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Abstract 
Purpose: To explore the effect of recombinant human erythropoietin (r-HuEPO) on apoptosis in rats 
after traumatic brain injury. 
Methods: A total of 48 traumatic brain-injured Sprague Dawley (SD) rats were obtained by improved 
Feeney’s traumatic brain injury model, and were randomly divided into four groups: normal saline-
treated rats (control) and rats treated with r-HuEPO at doses of 1000 U/kg, 3000 U/kg and 5000 U/kg. 
Brain tissues were collected on the 7th day after trauma surgery. Apoptotic cells, and NF-kappa B (NF-
ĸB)-, c-myc-, and Fas/Fasl-positive cells were identified in brain tissues by immunohistochemical assay. 
Results: After treatment with r-HuEPO (3000 and 5000 U/kg), expression of NF-κB and Fas/Fasl were 
significantly decreased (p < 0.05) compared to control rats, especially at the 5000 U/kg dose (p < 0.01). 
However, for c-myc, no significant difference was observed between r-HuEPO treatment and control 
groups (p > 0.05). Compared to the 1000 U/kg r-HuEPO group, Fas/Fasl expression levels were 
significantly lower in the 3000 and 5000 U/kg r-HuEPO groups (p < 0.05). Additionally, expression of 
NF-κB and Fasl in the 5000 U/kg r-HuEPO group was significantly lower than that in the 3000 U/kg r-
HuEPO group (p < 0.05). Moreover, the number of apoptotic cells in the r-HuEPO group (5000 U/kg) 
was significantly lower than in the control group (p < 0.05).  
Conclusion: Thus, r-HuEPO may be beneficial for treating traumatic brain injury via inhibition of NF-
kappa B and Fas/Fasl expressions. 
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Traumatic brain injury (TBI) is a major cause of 
death and persistent disability [1]. In addition, it is 
reported that over 5 % of patients with moderate 
injury, and 16 % of patients with severe injury 
would develop posttraumatic epilepsy [2,3]. The 
mechanisms underlying secondary brain damage 
following TBI are complex and involve two main 
stages: traumatic cerebral edema and delayed 
neuronal damage [1-3]. Delayed neuronal 
damage leads to irreversible necrosis or 
apoptosis of neurons, which could affect the 
long-term prognosis and quality of life in patients 
[1,2,4,5]. It is known that NF-kappa B (NF-κB) 
can result in neuronal damage by apoptosis. In 
addition, the c-myc gene could also promote 
apoptosis of neurons. Fatty acid synthase (Fas) 
is a transmembrane protein belonging to the 
tumor necrosis factor (TNF) superfamily. 
Interaction between Fas and its ligand (Fasl) is 
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one of the main pathways for inducing apoptosis 
[6-9]. 
 
Erythropoietin (EPO), which is mainly produced 
by the kidneys and liver, can affect hematopoietic 
stem cells present in the bone marrow. Recent 
research has indicated that EPO can be secreted 
by astrocytes (paracrine secretion) in the central 
nervous system (CNS) [10]. Furthermore, the 
secreted EPO could bind to the EPO receptors 
present on neuronal membranes nearby. 
Furthermore, EPO could also protect the nerves 
from secondary brain damage after TBI by 
relieving cerebrum edema [11], facilitating 
neuronal regeneration [12], lowering toxicity of 
excitatory amino acid neurotransmitters [13], and 
playing anti-oxidative effect [14]. Our present 
study used the r-HuEPO to treat traumatic brain 
injury in rats, and explore the effects of r-HuEPO 
on the expressions of NF-kB, c-myc and 






The r-HuEPO was purchased from the Shenyang 
Shansheng pharmaceutical Co., LTD (Shenyang, 
China); the primary antibodies of NF-kB and 
Fas/Fasl were purchased from the Santa Cruz 
Biotech. (Shanghai, China); the primary 
antibodies of c-myc were purchased by ZSGB 
Biotech (Shanghai, China); the secondary 
antibodies reagents of Envision were purchased 
from the Fuzhou Maixin Co., Ltd (Fuzhou, 
China). All the other chemical reagents used in 
our study were of analytical grade. 
 
TBI rat preparation and grouping 
 
A total of 48 healthy adult male SD rats 
(weighing between 280 and 320 g) were 
randomly divided into 4 groups: normal saline 
treated groups (control) and rhEPO treated 
groups at the doses of 1000 U/kg, 3000 U/kg 
rhEPO and 5000 U/kg. TBI rats were prepared 
by using the Modified Feeney's free-falling model 
[15]. The trauma preparation device consisted of 
steel weights falling freely by gravity from a 
designated height through a Plexiglas tube. The 
rats were anesthetized with 0.35 % pentobarbital 
sodium solution (30 mg/kg, intraperitoneal 
injection (ip). After exposing the left parietal bone 
by a midline incision, a port with 3 mm diameter 
was formed by dentistry auger. Thereafter, a 20 
g weight was dropped on the exposed dura from 
40 cm height. Drugs were administered 
immediately (ip) after trauma, and the drug was 
injected every 24 h until 7th day after trauma. All 
animal experiments were strictly accorded to the 
international ethical guidelines and the National 
Institutes of Health Guide concerning the Care 
and Use of Laboratory Animals, and the 
experiments were carried out followed the 
approval of the Animal Experimentation Ethics 
Committee of our Hospital (Ethical approval 
No.201312-A87). 
 
Sample collection and evaluation 
 
Brain tissues were collected at 7th day after 
trauma and fixed in formaldehyde. The damaged 
area of brain was imbedded with paraffin, and 
then, sliced. The NF-κB-, c-myc- and Fas/Fasl- 
positive cells, as well as apoptotic cells in brain 
tissues were detected by immuno-histochemistry 
assay. Cells with yellowish-brown grains in cell 
nucleus or endochylema were considered as 




All data are expressed as mean ± standard 
deviation (SD) and analyzed by SPSS 10.0 
statistical analysis software using analysis of 
variance (ANOVA). Differences were considered 




As shown in Table 1 and Plate 1, the positive 
expression levels of NF-κB and Fas/Fasl in r-
HuEPO treated TBI rats at the doses of 3000 and 
5000 U/kg were significantly decreased (p < 
0.05), compared with the normal saline treatment 
group (control group), particularly in the 5000 
U/kg treated group (p < 0.01). However, no 
significant difference in the c-myc expression 
was observed in each r-HuEPO treatment group 
(p > 0.05). Compared with the 1000 U/kg r-
HuEPO treated group, the positive expressions 
of c-myc and Fas/Fasl were significantly lower in 
3000 U/kg r-HuEPO group (p < 0.05), and the 
positive expression levels of NF-κB and Fas/Fasl 
in 5000 U/kg r-HuEPO treated group were 
significantly lower (p < 0.05). Compared with the 
3000 U/kg r-HuEPO treated group, only the 
positive expression levels of NF-κB and Fasl in 
5000 U/kg r-HuEPO group were significantly 
lower (p < 0.05). The results also indicated that 
the number of apoptotic cells in r-HuEPO treated 
group (5000 U/kg) was significantly lower 
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Table 1: Expressions of NF-κB, c-myc and Fas/Fasl, and number of apoptotic cells 
 
Group NF-κB c-myc Fas Fasl No. of apoptotic cells 
Control 48.83±7.42 35.51±8.98 44.80±7.30 35.91±5.37 62.18±7.05 
1000 46.79±6.28 40.20±5.65 40.18±7.58 33.11±8.46 54.40±8.45a 
3000  40.07±4.88a  32.73±8.60b  32.76±9.30ab  28.33±5.60ab 51.86±9.30a 
5000  32.92±6.75abc  34.97±9.63 33.50±6.09ab  22.52±3.87abc 45.57±6.90ab 
Data were represented as mean ± SD (n = 12); ap < 0.05, compared with control; bp<0.05, compared with 
1000U/kg; cp < 0.05, compared with 3000U/kg 
 
 
  Plate 1: Expressions of NF-κB, c-myc and Fas/Fasl in brain tissues (SP staining × 100) 
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After traumatic brain injury, the overexpression of 
pro-apoptotic genes will increase the tardus 
injury and irreversible degeneration necrosis or 
apoptosis of neurons, causing more serious 
consequences than traumatic brain edema. In 
this study, after traumatic brain injury, a large 
number of apoptotic cells were detected in the 
cerebral cortex of the control rats, indicating that 
neuronal apoptosis plays a curial role in 
secondary brain damage after traumatic brain 
injury. Interestingly, after treating with r-HuEPO, 
the expressions of pro-apoptotic proteins 
including NF-κB, c-myc and Fas/Fasl were 
significantly decreased compared with control 
group. In particular, after administration of r-
HuEPO at the dose of 5000 U/kg, the 
expressions of pro-apoptotic genes were 
suppressed most obviously. However, no 
obvious difference was observed in the r-HuEPO 
treatment rats for the expression of c-myc gene. 
The findings demonstrate that r-HuEPO has 
treatment effects on the expression of NF-κB, c-
myc, Fas and Fasl. In addition, our results also 
indicate that large dose of r-HuEPO has a strong 
suppressive effect on NF-κB and Fasl 
expression. 
 
Clinically reports revealed that prolonged usage 
of large doses of EPO may result in lots of side 
effects, such as increased blood volume, 
increased blood viscosity, and high blood 
pressure due to the proliferation of red blood 
cells [15,16]. Recently, Erbayraktar et al have 
developed a novel kind of EPO that does not 
contain the sialic acid group [17]. Interestingly, 
Erbayraktar found that this EPO did not promote 
the proliferation of red blood cells, and that it had 
a short half-life in the blood plasma, thereby 
avoiding the above-mentioned side effects. It 
also performed a better nerve-protective effect in 
the nervous system through the blood-brain 
barrier. Combined with the results of our study, it 
can be assumed that EPO might be used in 
clinical treatments to reduce neuronal damages 




The findings of this investigation suggest that 
EPO effectively suppresses the pro-apoptotic 
proteins, NF-κB and Fas/Fasl, after traumatic 
brain injuries in rats, and hence reduce neuronal 
damage. These findings provide some 
experimental evidence for the clinical use of EPO 
in treating severe traumatic brain injuries, 
especially in improving long-term prognosis and 
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